Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Acq. announced
Appointed director
Oxford Immunotec Global PLC (OXFD) Create: Alert

All | News | Filings
Date FiledTypeDescription
03/08/2021 8-K Quarterly results
02/26/2021 8-K Quarterly results
01/07/2021 8-K Quarterly results
11/30/2020 8-K Other Events, Financial Statements and Exhibits  Interactive Data
11/03/2020 8-K Quarterly results
Docs: " "
08/04/2020 8-K Quarterly results
06/25/2020 8-K Quarterly results
05/05/2020 8-K Quarterly results
04/21/2020 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Oxford Immunotec announces successful re-registration of the T-SPOT ® .TB test in China"
04/08/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
04/03/2020 8-K Other Events
03/02/2020 8-K Quarterly results
11/20/2019 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "FIRST AMENDMENT TO THE AMENDED AND RESTATED SUPPLY AND RESELLER AGREEMENT This First Amendment to the Amended and Restated Supply and Reseller Agreement is by and between Life Technologies Corporation , a Delaware corporation, with a principal business address at 29851 Willow Creek Road, Eugene, Oregon 97402 and Oxford Immunotec, Ltd. , a company incorporated under the laws of England and Wales, with a principal business address at 94C Innovation Drive, Milton Park, Abingdon, Oxfordshire, OX 14 4RZ, U.K., and is effective as of November 5, 2019 . WITNESSETH"
11/05/2019 8-K Quarterly results
Docs: "Oxford Immunotec Reports Third Quarter 2019 Financial Results"
09/17/2019 8-K Termination of a Material Definitive Agreement
08/06/2019 8-K Quarterly results
Docs: "Oxford Immunotec Reports Second Quarter 2019 Financial Results"
07/17/2019 8-K Entry into a Material Definitive Agreement
06/24/2019 8-K Quarterly results
06/14/2019 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Certain identified information has been excluded from this exhibit because such information both is not material and would likely cause competitive harm if publicly disclosed. Excluded information is indicated with brackets and asterisks. AMENDMENT OF AGREEMENT BETWEEN QUEST DIAGNOSTICS INCORPORATED and OXFORD IMMUNOTEC USA, INC. THIS AMENDMENT is effective as of the 1st day of January, 2019 , by and between Quest Diagnostics Incorporated and Oxford Immunotec USA, Inc. . WHEREAS, the parties have previously entered into a “Limited Liability Company Interest Purchase Agreement” dated September 25, 2018 ; and WHEREAS, Exhibit B to the Interest Purchase Agreement is an “Agreement to Purchase Test Kits and Accessories” between OI USA and Quest Diagnostics ; and WHEREAS, the parties, by this Am..."
05/09/2019 8-K Quarterly results
Docs: "Oxford Immunotec Reports First Quarter 2019 Financial Results"
03/21/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/21/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Oxford Immunotec Announces Chief Financial Officer Transition"
03/11/2019 8-K Other Events, Financial Statements and Exhibits
Docs: "Unaudited pro forma financial information"
03/11/2019 8-K Quarterly results
Docs: "Oxford Immunotec Reports Fourth Quarter and Full Year 2018 Financial Results"
03/11/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/08/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
01/11/2019 8-K Entry into a Material Definitive Agreement
01/10/2019 8-K Entry into a Material Definitive Agreement
01/08/2019 8-K Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
Docs: "Oxford Immunotec Announces Board Approval of $100 Million Share Repurchase Program and Reaffirms Growth Expectations for Fourth Quarter 2018"
01/07/2019 8-K Quarterly results
01/07/2019 8-K Other Events, Financial Statements and Exhibits
Docs: "Unaudited pro forma financial information"
11/09/2018 8-K Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Fina...
Docs: "Quest Diagnostics Completes Acquisition of U.S. Laboratory Services Business of Oxford Immunotec",
"Unaudited pro forma financial statements"
11/09/2018 8-K Quarterly results
Docs: "Oxford Immunotec Reports Third Quarter 2018 Financial Results",
"Unaudited Non-GAAP Pro Forma Condensed Combined Statement of Operations"
10/11/2018 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy